Get notified when OTLK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, which will not be alleviated by the net proceeds of this offering.
- Material Weakness (new) — No material weakness disclosure appears in the provided sections.
- Controlled Company (new) — No controlled company status is disclosed in the provided sections.
Outlook Therapeutics prices $5M direct offering at $0.59/share to single investor; net proceeds $4.5M
Filed May 29, 2026 · ~1 min read
Key Changes
-
high
Outlook Therapeutics is selling 8,539,709 shares at $0.59 per share directly to one accredited investor, raising $5.0 million gross and $4.5 million net for the company.
The Offering verify on EDGAR → -
medium
The company will use the net proceeds for working capital and general corporate purposes, with broad management discretion.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $0.67 per share, as the offering price is far above the company's net tangible book value per share.
Dilution verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade OTLK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify